CY1115312T1 - Συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει 3-{5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζοϋλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6- υλο)μεθοξυ]φαινυλο} προπιονικο οξυ ή αλας αυτου - Google Patents

Συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει 3-{5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζοϋλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6- υλο)μεθοξυ]φαινυλο} προπιονικο οξυ ή αλας αυτου

Info

Publication number
CY1115312T1
CY1115312T1 CY20141100428T CY141100428T CY1115312T1 CY 1115312 T1 CY1115312 T1 CY 1115312T1 CY 20141100428 T CY20141100428 T CY 20141100428T CY 141100428 T CY141100428 T CY 141100428T CY 1115312 T1 CY1115312 T1 CY 1115312T1
Authority
CY
Cyprus
Prior art keywords
benzyl
hydroxybenzoyl
cyclopentyloxy
hydroxy
phenyl
Prior art date
Application number
CY20141100428T
Other languages
English (en)
Inventor
Sahoe Kakuda
Tatsuhito Yahata
Masashi Kaneko
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of CY1115312T1 publication Critical patent/CY1115312T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Mια σύνθεση για χορήγηση από το στόμα που περιέχει 3-{5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζόυλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6-υλο)μεθοξυ]φαινυλο}προπιονικό οξύ ή ένα άλας αυτού και πολυβινυλοπυρρολιδόνη, είναι πλεονεκτική ως μια στοματική φαρμακευτική σύνθεση (1) η οποία μπορεί να παραχθεί χωρίς να απαιτείται νέος εξοπλισμός παρασκευής· (2) η οποία μπορεί να παραχθεί με απλά βήματα· (3) η οποία διατηρεί σταθερή διαλυτότητα ακόμη και με τις αλλαγές στο pΗ της γαστρεντερικής οδού και της οποίας η απορρόφηση δια της γαστρεντερικής οδού είναι βελτιωμένη.
CY20141100428T 2006-05-26 2014-06-11 Συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει 3-{5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζοϋλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6- υλο)μεθοξυ]φαινυλο} προπιονικο οξυ ή αλας αυτου CY1115312T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006146315 2006-05-26
JP2006146257 2006-05-26
EP07744105.3A EP2022497B1 (en) 2006-05-26 2007-05-25 Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof

Publications (1)

Publication Number Publication Date
CY1115312T1 true CY1115312T1 (el) 2017-01-04

Family

ID=38778517

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100428T CY1115312T1 (el) 2006-05-26 2014-06-11 Συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει 3-{5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζοϋλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6- υλο)μεθοξυ]φαινυλο} προπιονικο οξυ ή αλας αυτου

Country Status (21)

Country Link
US (1) US8093289B2 (el)
EP (1) EP2022497B1 (el)
JP (1) JP5161077B2 (el)
KR (1) KR101394121B1 (el)
CN (1) CN101454003B (el)
AU (1) AU2007268772B2 (el)
BR (1) BRPI0709710A2 (el)
CA (1) CA2653023C (el)
CY (1) CY1115312T1 (el)
DK (1) DK2022497T3 (el)
ES (1) ES2463455T3 (el)
IL (1) IL195417A (el)
MX (1) MX2008015015A (el)
NO (1) NO20084634L (el)
NZ (1) NZ573035A (el)
PL (1) PL2022497T3 (el)
PT (1) PT2022497E (el)
RU (1) RU2436576C2 (el)
SI (1) SI2022497T1 (el)
WO (1) WO2007138997A1 (el)
ZA (1) ZA200810018B (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716082A1 (en) * 2008-03-04 2009-02-23 F. Hoffmann-La Roche Ag Process for preparing concentrated aqueous micellar solutions
DK2258361T3 (da) * 2008-03-27 2014-10-27 Toyama Chemical Co Ltd ANVENDELSE AF ET BENZOPHENONDERIVAT ELLER ET SALT DERAF I KOMBINATION MED EN TNFalfa-INHIBITOR OG FARMACEUTISK SAMMENSÆTNING INDEHOLDENDE DERIVATET ELLER SALTET DERAF OG INHIBITOREN
WO2009131098A1 (ja) 2008-04-22 2009-10-29 富山化学工業株式会社 ベンゾフェノン誘導体またはその塩および免疫抑制剤を組み合わせて使用する方法ならびにこれらを含有する医薬組成物
EP2140861A1 (en) 2008-06-30 2010-01-06 Abbott GmbH & Co. KG Pharmaceutical dosage form comprising polymeric carrier composition
EP2908806A1 (en) * 2012-10-09 2015-08-26 Boehringer Ingelheim International GmbH Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
CN110575762B (zh) * 2018-06-07 2024-03-26 温州大学新材料与产业技术研究院 一种有机烷基钆水性分散体系的制备方法
WO2021257887A1 (en) * 2020-06-19 2021-12-23 The Board Of Trustees Of The Leland Stanford Junior University Use of inhibitors of the activator protein 1 (ap-1) for preventing adhesions
JP7495340B2 (ja) 2020-12-16 2024-06-04 株式会社ファンケル カルノシン酸含有固体組成物及びカルノシン酸の溶出促進方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670080A (en) * 1969-03-06 1972-06-13 Shionogi & Co Process for stabilization of a composition of 2{60 ,3{60 -epithio-androstanes and composition obtained thereby
JPS55129221A (en) * 1979-03-29 1980-10-06 Kaken Pharmaceut Co Ltd Preparation of oral preparation containing hardly soluble medicine
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
JPS5942313A (ja) * 1982-09-01 1984-03-08 Teijin Ltd ポリビニルポリピロリドンを用いた製剤
JPS60190723A (ja) * 1984-03-09 1985-09-28 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
BR0214177A (pt) * 2001-11-16 2004-09-14 Toyama Chemical Co Ltd Derivado de benzofenona, agente preventivo ou terapêutico para uma doença em que está envolvida expressão excessiva de ap-1, e, inibidor de ap-1

Also Published As

Publication number Publication date
US20090163562A1 (en) 2009-06-25
KR20090021167A (ko) 2009-02-27
SI2022497T1 (sl) 2014-08-29
DK2022497T3 (da) 2014-05-19
EP2022497B1 (en) 2014-04-30
CA2653023C (en) 2015-07-07
IL195417A (en) 2014-03-31
AU2007268772A1 (en) 2007-12-06
ES2463455T3 (es) 2014-05-28
AU2007268772B2 (en) 2012-03-15
IL195417A0 (en) 2009-08-03
EP2022497A1 (en) 2009-02-11
PL2022497T3 (pl) 2014-09-30
BRPI0709710A2 (pt) 2011-07-26
MX2008015015A (es) 2008-12-05
RU2436576C2 (ru) 2011-12-20
WO2007138997A1 (ja) 2007-12-06
CA2653023A1 (en) 2007-12-06
CN101454003B (zh) 2011-06-01
RU2008151757A (ru) 2010-07-10
EP2022497A4 (en) 2013-02-13
PT2022497E (pt) 2014-07-17
CN101454003A (zh) 2009-06-10
KR101394121B1 (ko) 2014-05-14
JPWO2007138997A1 (ja) 2009-10-08
US8093289B2 (en) 2012-01-10
ZA200810018B (en) 2010-02-24
NZ573035A (en) 2010-08-27
JP5161077B2 (ja) 2013-03-13
NO20084634L (no) 2008-12-19

Similar Documents

Publication Publication Date Title
CY1115312T1 (el) Συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει 3-{5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζοϋλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6- υλο)μεθοξυ]φαινυλο} προπιονικο οξυ ή αλας αυτου
CY1108455T1 (el) Νεος στεροειδης αγωνιστης δια fxr
RU2010151410A (ru) Производные аминодигидротиазина
DK1856045T3 (da) 1-eddikesyreindolderviater med PGD2-antagonisteffekt
DE602007005241D1 (de) Purin-derivate als a2a-rezeptor-agonisten
RS50437B (sr) Benzoilpirazoli i njihova primena u ulozi herbicida
CY1112086T1 (el) Συνδυασμος γλυκοπυρρολικου αλατος και ενος αγωνιστη βητα2 αδρενεργικων υποδοχεων
TW200745099A (en) Optically active thiazolidinedione derivatives
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
EA200200876A1 (ru) Алкилированные производные имидазопиридина
UY30788A1 (es) Compuestos quimicos
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
CY1111432T1 (el) Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5
CY1115787T1 (el) Διαδικασια για την παραγωγη 3-[5-[4-(κυκλοπεντυλοξυ)-2-υδροξυβενζοϋλο]-2-[(3-υδροξυ-1,2-βενζισοξαζολ-6-υλο)μεθοξυ]φαινυλο]προπιονικου εστερα και ενδιαμεση για την διαδικασια
DK1906938T3 (da) Farmaceutisk formulering af nitrooxyderivater af NSAID'er
RU2008151778A (ru) Новые кристаллы 3-[5-[4-(циклопентилокси)-2-гидроксибензоил]-2-[(3-гидрокси-1,2-бензизоксазол-6-ил)метокси]фенил]пропиновой кислоты
ITMI20040235A1 (it) Preparazione farmaceutica per il cavo orale
ATE468329T1 (de) Isoxazolderivate und deren verwendung als cyclooxygenaseinhibitoren
ATE278667T1 (de) Tetramsäure-derivate zur verwendung in medizin und lebensmitteltechnologie
TH83580A (th) สารประกอบชนิดใหม่
TH90585B (th) สารประกอบทางเภสัชกรรมชนิดใหม่
WO2009069643A1 (ja) ３－｛５－［４－（シクロペンチルオキシ）－２－ヒドロキシベンゾイル］－２－［（３－ヒドロキシ－１，２－ベンズイソオキサゾール－６－イル）メトキシ］フェニル｝プロピオン酸またはその塩を含有する固体分散体またはその組成物
DE50303885D1 (de) Beta-isoindigofarbmittel
EA200700206A1 (ru) Соль щавелевой кислоты с 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-дионом, способ её получения и применение
SE0401308L (sv) Anordning för lampanslutning